NewAmsterdam Pharma (NAMS) Change in Cash (2023 - 2026)

NewAmsterdam Pharma (NAMS) has 4 years of Change in Cash data on file, last reported at -$31.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash fell 14.59% year-over-year to -$31.0 million; the trailing twelve-month figure through Mar 2026 stood at -$297.1 million (down 210.95% YoY), and the FY2025 full-year result was -$293.2 million, down 166.92% from the prior year.
• Change in Cash climbed to -$31.0 million in Q1 2026, from -$48.3 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $357.0 million in Q4 2024 to a low of -$193.4 million in Q2 2025.
• A 4-year average of -$1.4 million and a median of -$29.5 million in 2023 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash jumped 1179.15% in 2024 and slumped 290.43% in 2025, its largest moves.
• Tracing NAMS's Change in Cash over 4 years: stood at -$33.1 million in 2023, then jumped by 1179.15% to $357.0 million in 2024, then tumbled by 113.54% to -$48.3 million in 2025, then soared by 35.76% to -$31.0 million in 2026.
• Business Quant data shows NAMS's Change in Cash at -$31.0 million in Q1 2026, -$48.3 million in Q4 2025, and -$24.4 million in Q3 2025.